Drug Profile

Zorevunersen - Stoke Therapeutics

Alternative Names: STK-001

Latest Information Update: 05 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stoke Therapeutics
Class Antiepileptic drugs; Antisense oligonucleotides; Neuroprotectants
Mechanism of Action Gene silencing; NAV1.1 voltage-gated sodium channel expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Dravet syndrome
New Molecular Entity Yes

Highest Development Phases

Phase III Dravet syndrome

Most Recent Events

27 Jan 2026 Stoke plan to launch zorevunersen for Dravet Syndrome in USA
11 Jan 2026 Stoke Therapeutics announces intention to submit NDA to US FDA for Dravet syndrome in first half of 2027
02 Sep 2025 Pooled efficacy and safety data from the phase I/IIa and open-label extension (OLE) studies in Dravet syndrome released by Stoke Therapeutics, and Biogen

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com